Cell Biotech Co. Ltd (049960) - Total Assets
Based on the latest financial reports, Cell Biotech Co. Ltd (049960) holds total assets worth ₩134.57 Billion KRW (≈ $91.20 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See 049960 net asset value for net asset value and shareholders' equity analysis.
Cell Biotech Co. Ltd - Total Assets Trend (2011–2024)
This chart illustrates how Cell Biotech Co. Ltd's total assets have evolved over time, based on quarterly financial data.
Cell Biotech Co. Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Cell Biotech Co. Ltd's total assets of ₩134.57 Billion consist of 74.5% current assets and 25.5% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩-50.00 | 3.7% |
| Accounts Receivable | ₩4.56 Billion | 3.5% |
| Inventory | ₩4.20 Billion | 3.2% |
| Property, Plant & Equipment | ₩30.46 Billion | 23.4% |
| Intangible Assets | ₩1.61 Billion | 1.2% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2011–2024)
This chart illustrates how Cell Biotech Co. Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of Cell Biotech Co. Ltd.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Cell Biotech Co. Ltd's current assets represent 74.5% of total assets in 2024, an increase from 0.0% in 2011.
- Cash Position: Cash and equivalents constituted 3.7% of total assets in 2024, down from 21.8% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, a decrease from 2.0% in 2011.
- Asset Diversification: The largest asset category is property, plant & equipment at 23.4% of total assets.
Cell Biotech Co. Ltd Competitors by Total Assets
Key competitors of Cell Biotech Co. Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Pluristem
TA:PSTI
|
Israel | ILA79.13 Million |
|
Hadasit Bio
TA:HDST
|
Israel | ILA14.67 Million |
|
Purple Biotech Ltd
TA:KTOV
|
Israel | ILA85.78 Million |
|
Peptron Inc
KQ:087010
|
Korea | ₩183.74 Billion |
|
MEDIPOST Co. Ltd
KQ:078160
|
Korea | ₩374.57 Billion |
|
Bioneer Corporation
KQ:064550
|
Korea | ₩376.52 Billion |
|
Macrogen Inc
KQ:038290
|
Korea | ₩341.60 Billion |
|
Panagene Inc
KQ:046210
|
Korea | ₩101.91 Billion |
Cell Biotech Co. Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 13.72 | 16.33 | 14.02 |
| Quick Ratio | 13.11 | 15.58 | 13.26 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩93.72 Billion | ₩83.83 Billion | ₩60.28 Billion |
Cell Biotech Co. Ltd - Advanced Valuation Insights
This section examines the relationship between Cell Biotech Co. Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.76 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 10.8% |
| Total Assets | ₩130.40 Billion |
| Market Capitalization | $83.71 Million USD |
Valuation Analysis
Below Book Valuation: The market values Cell Biotech Co. Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Cell Biotech Co. Ltd's assets grew by 10.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Cell Biotech Co. Ltd (2011–2024)
The table below shows the annual total assets of Cell Biotech Co. Ltd from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩130.40 Billion ≈ $88.37 Million |
+10.84% |
| 2023-12-31 | ₩117.64 Billion ≈ $79.72 Million |
+1.56% |
| 2022-12-31 | ₩115.84 Billion ≈ $78.50 Million |
+2.62% |
| 2021-12-31 | ₩112.88 Billion ≈ $76.49 Million |
+7.19% |
| 2020-12-31 | ₩105.30 Billion ≈ $71.36 Million |
-2.77% |
| 2019-12-31 | ₩108.30 Billion ≈ $73.40 Million |
-3.34% |
| 2018-12-31 | ₩112.05 Billion ≈ $75.93 Million |
+16.14% |
| 2017-12-31 | ₩96.48 Billion ≈ $65.38 Million |
+6.57% |
| 2016-12-31 | ₩90.53 Billion ≈ $61.35 Million |
+20.76% |
| 2015-12-31 | ₩74.97 Billion ≈ $50.80 Million |
+30.14% |
| 2014-12-31 | ₩57.60 Billion ≈ $39.04 Million |
+23.35% |
| 2013-12-31 | ₩46.70 Billion ≈ $31.65 Million |
+15.86% |
| 2012-12-31 | ₩40.30 Billion ≈ $27.31 Million |
+9.69% |
| 2011-12-31 | ₩36.75 Billion ≈ $24.90 Million |
-- |
About Cell Biotech Co. Ltd
Cell Biotech Co., Ltd., a biotechnology company, develops and sells lactic acid bacteria in South Korea. It also offers probiotic products under the Nutra DUOLAC, LACTOClear, and LAB2PRO brands. The company also exports its products to approximately 40 countries, including the United States, Europe, Japan, and China. Cell Biotech Co., Ltd. was founded in 1995 and is based in Gimpo-si, South Korea.